(Reuters) - Gilead Sciences Inc on Thursday posted worse-than-expected quarterly results, but raised its 2020 sales forecast to include revenue from its antiviral drug remdesivir, one...
read full article...
Gilead raises sales outlook to include COVID-19 treatment remdesivir